Endometrial cancer - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main endometrial cancer page for regimens that include active anticancer treatment.
=Neoadjuvant therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Kitson et al. 2018 (PREMIUM)	2015-2017 	Phase 3 (C)	Metformin 	Did not meet primary endpoint of posttreatment IHC expression of Ki-67
No active antineoplastic treatment prior to surgery.
====Subsequent treatment====
*Surgery
===References===
# PREMIUM: Kitson SJ, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton PW, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial. Clin Cancer Res. 2019 Apr 15;25(8):2424-2432. Epub 2018 Dec 18. link to original article link to PMC article EuroPMC ISRCTN88589234
=Adjuvant therapy=
==Observation==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Omura et al. 1985 (GOG 20) 	1973-1982 	Phase 3 (C)	Doxorubicin 	Did not meet efficacy endpoints
Keys et al. 2004 (GOG 99) 	1987-1995 	Phase 3 (C)	RT 	Shorter RFS
Hogberg et al. 2010 (EORTC 55991) 	1996-2007 	Phase 3 (C)	1a. Cisplatin & Doxorubicin1b. Cisplatin & Epirubicin1c. Epirubicin & Paclitaxel1d. Carboplatin & Doxorubicin1e. Carboplatin & Paclitaxel	Seems to have shorter PFS
Hogberg et al. 2010 (MaNGO ILIADE-III)	1998-2007 	Phase 3 (C)	Cisplatin & Doxorubicin 	Did not meet primary endpoint of PFS
No further treatment.
====Preceding treatment====
*GOG 20, GOG 99, MaNGO ILIADE-III: Surgery
*EORTC 55991: Surgery, then adjuvant RT
====Subsequent treatment====
*MaNGO ILIADE-III: Adjuvant RT
===References===
# GOG 20: Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Sep;3(9):1240-5. link to original article EuroPMC
# GOG 99: Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG; Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar;92(3):744-51. Erratum in: Gynecol Oncol. 2004 Jul;94(1):241-2. link to original article EuroPMC
# EORTC 55991: Hogberg T, Signorelli M, Freire de Oliveira C, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010 Sep;46(13):2422-31. Epub 2010 Jul 7. link to original article link to PMC article EuroPMC NCT00005583
# MaNGO ILIADE-III: Hogberg T, Signorelli M, Freire de Oliveira C, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010 Sep;46(13):2422-31. Epub 2010 Jul 7. link to original article link to PMC article EuroPMC
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Barakat et al. 2006 (GOG 137A)	1997-2003 	Phase 3 (C)	Estrogen replacement therapy	Did not meet primary endpoint of RFS
No active antineoplastic treatment. Note that this trial was stopped early due to the increased risk of ERT in the Women's Health Initiative trial, and should be considered inconclusive.
====Preceding treatment====
*Hysterectomy
===References===
# GOG 137A: Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Feb 1;24(4):587-92. link to original article EuroPMC NCT00002976
=Maintenance after first-line therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Vergote et al. 2023 (SIENDO)	2018-01 to 2021-12 	Phase 3 (C)	Selinexor 	Did not meet primary endpoint of PFS
====Preceding treatment====
*First-line platinum-based chemotherapy
===References===
#SIENDO: Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. Epub 2023 Sep 5. link to original article EuroPMC NCT03555422
Category:Endometrial cancer regimens
Category:Disease-specific pages
Category:Gynecologic cancers
Category:Null regimens